Azienda Ospedaliera Papa Giovanni XXIII Hematology and Bone Marrow Transplant Unit Bergamo Italy

Charles University Hospital Dept of Hematology Oncology Pilsen Czech Republic

CHU Nantes Dept D'Hématologie Nantes France;

Department of Hematology Hospital Clinic IDIBAPS Barcelona Spain

Department of Internal Medicine Bone Marrow Transplantation Program American University of Beirut Medical Center Beirut

Department of Internal Medicine Bone Marrow Transplantation Program American University of Beirut Medical Center Beirut Department of Blood and Marrow Transplantation H Lee Moffitt Cancer Center University of South Florida College of Medicine Tampa Florida

Department of Medicine Helsinki Finland

Deutsche Klinik für Diagnostik KMT Zentrum Wiesbaden Germany

EBMT Paris study office CEREST TC France Department of Hematology Saint Antoine Hospital Paris France INSERM UMR 938 Paris France Université Pierre et Marie Curie Paris France

EBMT Paris study office CEREST TC France Tel Aviv University Chaim Sheba Medical Center Tel Hashomer Israel

Gustave Roussy institut de cancérologie BMT Service Division of Hematology Department of Medical Oncology Villejuif France

Hopital Jean Minjoz Service d' Hématologie Besancon France

Hopital St Louis Dept of Hematology BMT Paris France

Klinikum Augsburg 2 Medizinische Klinik Augsburg Germany

Programme de Transplantation and Therapie Cellulaire Centre de Recherche en Cancérologie de Marseille Institut Paoli Calmettes Marseille France

Rikshospitalet Department of Medicine The National Hospital Oslo Norway

SCT Unit Klinikum Augsburg Germany;

Zobrazit více v PubMed

Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484–495. PubMed

Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–1062. PubMed

Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365. PubMed

Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–4380. PubMed

Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. PubMed PMC

Ostronoff F, Othus M, Lazenby M, et al. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol. 2015;33(10):1157–1164. PubMed PMC

Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117(4):1109–1120. PubMed

Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747–3754. PubMed

Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733–3739. PubMed

Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–1918. PubMed

Kienast J, Beelen DW, Kolb HJ, et al. Allogeneic Hematopoietic Stem Cell Transplantation (Allo-SCT) Versus Conventional Postremission Therapy (PRT) for AML in First Complete Remission (CR1): A Matched Pairs Analysis Based on Data of the AML Cooperative Group (AMLCG) 1999 Trial. Blood. 2007;110(11):328 abstr.

Rollig C, Bornhauser M, Kramer M, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol. 2015;33(5):403–410. PubMed

Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia